Liposomal camptothecins and uses thereof
AssigneeTekmira Pharmaceuticals Corporation
InventorsThomas D. MADDEN, Sean F. SEMPLE
Life of this patent
Estimating the term…
Abstract
This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
Claims25
A liposomal topotecan unit dosage form, said unit dosage form comprising:
- a lipid;
- and a topotecan dosage of from about 0.01 mg/M2/dose to about 7.5 mg/M2/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio (by weight) of about 0.05 to about 0.2.
A liposomal topotecan formulation, wherein said liposomal topotecan formulation retains greater than 50% active lactone species after 12 hours in blood circulation.
A liposomal topotecan formulation comprising topotecan, sphingomyelin, cholesterol and a divalent cation ionophore.
A method of treating solid tumors in a mammal, said method comprising:
- administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation having a drug:lipid ratio (by weight) of about 0.05 to about 0.2.
A method of treating solid tumors in a mammal, said method comprising:
- administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 mg/M2/dose to about 7.5 mg/M2/dose of topotecan for an interval regime, wherein said interval regime is once a day for at least two consecutive days.
A method of treating solid tumors in a mammal comprising administering to an animal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 to about 7.5 mg/M2/dose of topotecan every three days.
A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from about 0.015 mg/M2/dose to about 1 mg/M2/dose and having a drug:lipid ratio (by weight) of about 0.05 to about 0.2.
The use of topotecan in the manufacture of a medicament comprising a liposome having a sphingomyelin to cholesterol ratio (by weight) of from about 30:70 to about 60:40 for use in treating solid tumors in a mammal.
Dependencies are inferred from the claim text.